Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDES-BLEED: Desmopressin in High-Risk Cardiac Surgery
NCT07012837Phase 3Not yet recruiting
- Sponsor
- Imam Abdulrahman Bin Faisal University
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Postoperative bleeding comparing Desmopressin with Placebo (2 arms). Primary endpoint: Cumulative 48-hour postoperative bleeding. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
desmopressin
03
Conditions
Postoperative bleeding
Beyond the preview
Go deeper on NCT07012837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012837.